This study is an open-label prospective interventional trial that will assess the efficacy of
ruxolitinib in the treatment of seborrheic dermatitis. It will also attempt to characterize
the molecular immune profiles of patients with SD at week 0 and week 4, with comparison to
baseline profiles in healthy control subjects.